scholarly journals Insulin/IGF-1 Signaling is Downregulated in Barrett’s Esophagus Patients Undergoing a Moderate Calorie and Protein Restriction Program: A Randomized 2-Year Trial

Nutrients ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 3638
Author(s):  
Diletta Arcidiacono ◽  
Alice Zaramella ◽  
Federico Fabris ◽  
Ricardo Sánchez-Rodríguez ◽  
Daniele Nucci ◽  
...  
Keyword(s):  
Risk Factors ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Intervention Program ◽  
Protein Restriction ◽  
Anthropometric Parameters ◽  
Simultaneous Reduction ◽  
Cancer Risk Factors ◽  
Igf Binding ◽  
Igf Binding Protein

Obesity and associated insulin resistance (Ins-R) have been identified as important risk factors for esophageal adenocarcinoma development. Elevated calories and protein consumption are also associated with Ins-R and glucose intolerance. We investigated the effect of a 24-month moderate calorie and protein restriction program on overweight or obese patients affected by Barrett’s esophagus (BE), as no similar dietary approach has been attempted to date in this disease context. Anthropometric parameters, levels of serum analytes related to obesity and Ins-R, and the esophageal insulin/IGF-1 signaling pathway were analyzed. This study is registered with ClinicalTrials.gov, number NCT03813381. Insulin, C-peptide, IGF-1, IGF-binding protein 3 (IGFBP3), adipokines, and esophageal expression of the main proteins involved in insulin/IGF-1 signal transduction were quantified using Luminex-XMAP® technology in 46 patients who followed the restriction program (IA) and in 54 controls (CA). Body mass index and waist circumference significantly decreased in 76.1% of IA and 35.2% of CA. IGF-1 levels were reduced in 71.7% of IA and 51.8% of CA. The simultaneous reduction of glycaemia, IGF-1, the IGF-1/IGFBP3 ratio, and the improvement in weight loss-dependent insulin sensitivity, were associated with the downregulation of the insulin/IGF-1 signal on BE tissue. The proposed intervention program was an effective approach to counteract obesity-associated cancer risk factors. The improvement in metabolic condition resulted in a downregulation of the ERK-mediated mitogenic signal in 43.5% of patients, probably affecting the molecular mechanism driving adenocarcinoma development in BE lesions.

Cancer risk factors associated with insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels in healthy women: effect modification by menopausal status

2009 ◽  
Vol 20 (10) ◽  
pp. 1985-1996 ◽  
Author(s):  
Benjamin B. E. Barnes ◽  
Jenny Chang-Claude ◽  
Dieter Flesch-Janys ◽  
Ralf Kinscherf ◽  
Martina Schmidt ◽  
...  
Keyword(s):  
Risk Factors ◽  
Growth Factor ◽  
Cancer Risk ◽  
Menopausal Status ◽  
Effect Modification ◽  
Cancer Risk Factors ◽  
Factors Associated ◽  
Igf I ◽  
Igf Binding ◽  
Igf Binding Protein

scholarly journals Cancer Prevention in Patients with GERD and Barrett’s Esophagus—Medicine

2021 ◽  
Vol 1 (1) ◽  
pp. 50-62
Author(s):  
Carmelo Scarpignato ◽  
David H. Wang
Keyword(s):  
Risk Factors ◽  
Reactive Oxygen Species ◽  
Cell Proliferation ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Acid Reflux ◽  
Oxygen Species ◽  
Esophageal Reflux ◽  
Early Disease ◽  
Chemopreventive Agents

Gastro-esophageal reflux disease (GERD) and Barrett’s esophagus are risk factors for esophageal adenocarcinoma (EAC). Chemoprevention is an attractive strategy, more effective than identifying early disease. Since acid reflux can lead to increased cell proliferation, decreased apoptosis, production of reactive oxygen species, DNA damage, and esophageal production of proinflammatory and pro-proliferative cytokines, proton pump inhibitors (PPIs) alone, or in combination with COX-inhibition, are the most suitable chemopreventive agents. Other compounds (statins, metformin, and selected nutraceuticals) cannot currently be recommended. Data are strong enough to warrant PPI treatment of virtually all patients with Barrett’s esophagus, although the best regimen has not yet been defined.

Correlation Between Traditional Barrett's Esophagus Risk Factors and Gastroesophageal Acid Reflux and Esophageal Mucosal Injury

2020 ◽  
Author(s):  
Christopher Toivonen ◽  
Sirish Rao ◽  
Yazan Addasi ◽  
Ryan W. Walters ◽  
Kalyana Nandipati ◽  
...  
Keyword(s):  
Risk Factors ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Mucosal Injury ◽  
Acid Reflux

scholarly journals Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort

2019 ◽  
Author(s):  
K Y Song ◽  
A J Henn ◽  
A A Gravely ◽  
H Mesa ◽  
S Sultan ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Independent Risk Factor ◽  
High Grade Dysplasia ◽  
Low Grade ◽  
High Grade ◽  
Increased Risk ◽  
Low Grade Dysplasia

SUMMARY Patients with Barrett's esophagus (BE) and low-grade dysplasia (LGD) are at increased risk of esophageal adenocarcinoma (EAC), although many regress to nondysplastic BE. This has significant clinical importance for patients being considered for endoscopic eradication therapy. Our aim is to determine the risk for progression in patients with confirmed persistent LGD. We performed a single-center retrospective cohort study of patients with BE and confirmed LGD between 2006 and 2016. Confirmed LGD was defined as LGD diagnosed by consensus conference with an expert GI pathologist or review by an expert GI pathologist and persistence as LGD present on subsequent endoscopic biopsy. The primary outcome was the incidence rate of HGD (high-grade dysplasia)/EAC. Secondary outcomes included risk factors for dysplastic progression. Risk factors for progression were assessed using univariate and multivariate analysis with logistic regression. Of 69 patients (mean age 65.2 years) with confirmed LGD were included. In total, 16 of 69 patients (23.2%) with LGD developed HGD/EAC during a median follow-up of 3.74 years (IQR, 1.24–5.45). For persistent confirmed LGD, the rate was 6.44 (95% confidence interval (CI), 2.61–13.40) compared to 2.61 cases per 100 patient-years (95% CI, 0.83–6.30) for nonpersistent LGD. Persistent LGD was found in only 29% of patients. Persistent LGD was an independent risk factor for the development of HGD/EAC (OR 4.18; [95% CI, 1.03–17.1]). Persistent confirmed LGD, present in only 1/3 of patients, was an independent risk factor for the development of HGD/EAC. Persistence LGD may be useful in decision making regarding the management of BE.

Prevalence of and risk factors for Barrett's esophagus with intestinal predominant mucin phenotype

2006 ◽  
Vol 41 (8) ◽  
pp. 873-879 ◽  
Author(s):  
Yuji Amano ◽  
Yoshinori Kushiyama ◽  
Takafumi Yuki ◽  
Yoshiko Takahashi ◽  
Ichiro Moriyama ◽  
...  
Keyword(s):  
Risk Factors ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Mucin Phenotype

Risk Factors for Prevalent Adenocarcinomas in Patients With High-Grade Dysplasia in Barrett's Esophagus: A Dutch Population-Based Study

2011 ◽  
Vol 140 (5) ◽  
pp. S-667 ◽  
Author(s):  
Romy E. Verbeek ◽  
Martijn G. van Oijen ◽  
Fiebo J. ten Kate ◽  
Frank P. Vleggaar ◽  
Marguerite E. Schipper ◽  
...  
Keyword(s):  
Risk Factors ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Population Based ◽  
High Grade Dysplasia ◽  
High Grade ◽  
Dutch Population ◽  
Population Based Study
Sign in / Sign up

Export Citation Format

Share Document